Global Partners
GLP
42.13
-1.13
-2.61%
Global Partners
US · GLP
#2946 by market cap
Listed 1970
42.13
-1.13
-2.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Leading Novo Nordisk! China's first oral GLP-1 weight-loss drug has been approved and production has already begun ahead of schedule.cls.cn · 2026/11/12
-
Rating change
TR | OpenAI - 4o Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53Market Newswire · 2025/8/11
-
Rating change
Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term UpsideTipRanks · 2026/2/12
-
U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk -- WSJWSJ · 2026/11/9
-
Company notice
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/GHKEX · 2026/8/10
-
Multiple GLP-1 injectables have been included in the National Reimbursement Drug List (NRDL) for the first time, including products from Pfizer and Innovent Biologics, for the treatment of type 2 diabetes in adults.Sina Tech · 2026/11/14
-
Company notice
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1RHKEX · 2026/7/6
-
Company notice
GLP J-REIT: Aug. 2026 (29th) FISCAL PERIODJPX · 2026/10/15
-
Rating change
Stifel Maintains Global Partners(GLP.US) With Hold Rating, Cuts Target Price to $45Market Newswire · 2025/11/11
-
Rating change
Raymond James Initiates Global Partners(GLP.US) With Hold RatingMarket Newswire · 2026/8/11
-
Company notice
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATEDPLACEBO-ADJUSTED HBA1C REDUCTION OF 1.7% AT 12 WEEKS FROMITS U.S. PHASE II STUDY IN PARTICIPANTS WITH DIABETESHKEX · 2026/10/29
-
Rating change
Morgan Stanley: Hims' Target Price is $40 with an 18% downside potential, and the GLP-1 lawsuit tug-of-war is the biggest variable.Zhitong Finance · 2025/7/9
-
Rating change
TR | OpenAI - 4o Downgrades Global Partners(GLP.US) to Hold Rating, Cuts Target Price to $57Market Newswire · 2025/8/6
-
Rating change
Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification.Northeast Securities · 2026/6/11
-
Company notice
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT -ASCLETIS SUBMITS IND APPLICATION TO THE U.S. FDA FOR ASC30_39FDC, A POTENTIALLY FIRST-IN-CLASS ORAL SMALL MOLECULEFIXED-DOSE COMBINATION OF GLP-1R AGONIST AND SELECTIVEAMYLIN RECEPTOR AGONIST, FOR THE TREATMENT OF OBESITYHKEX · 2026/11/11
-
Rating change
CLSA: Upgrades Fosun Pharma (02196) target price to HKD 31.6 following GLP-1 drug collaboration with Pfizer (PFE.US).Zhitong Finance · 2025/12/10
-
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of ObesityPR Newswire · 2026/11/11
-
Rating change
Stifel Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53Market Newswire · 2025/8/13
-
Hims & Hers Struck a GLP-1 Deal With Lilly. Its Stock Is Rallying.MarketWatch · 2026/11/7
-
Rating change
GLP-1 drugs reshape consumer habits, and Wall Street rarely lowers McDonald's rating.wallstreetcn · 2025/6/10
-
Company notice
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITYHKEX · 2026/6/23
-
Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)TipRanks · 2026/10/22
-
Ascletis Pharma-B (01672.HK): In the U.S. Phase II study of ASC30, an oral small-molecule GLP-1 agent, among subjects with diabetes, placebo-adjusted glycated hemoglobin (HbA1c) reduction reached 1.7% at Week 12.Gelonghui Finance · 2026/10/29
-
Eli Lilly and Co. reported a 39% year-over-year increase in Q3 revenue, significantly exceeding expectations, with GLP-1 accounting for over 60% of its revenue, and raised its full-year guidance for the third time this year.wallstreetcn · 2026/10/29
-
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks From Its U.S. Phase II Study in Participants With DiabetesPR Newswire · 2026/10/29
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Global Partners discussion 0 comments